BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

Singapore approves Respiree's 1Bio™AI-Acute toolbox to support healthcare

10 December 2025 | News

Respiree to expand the 1Bio™AI-Acute regulatory approvals across other APAC and ANZ regions, and US

1Bio AI RISK INFORMATICS FOR ACUTE CARE

Singapore-based health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD).

The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio™AI-Acute delivers significantly higher precision in acute deterioration notifications, resulting in fewer false alerts and more efficient clinical support.

The 1Bio™AI-Acute system uses only bedside-recorded vital signs—pulse rate, respiratory rate, oxygen saturation, and systolic blood pressure—to generate a probability score that assists clinicians in determining whether additional monitoring may be required. This score provides an indication of the patient's general physiological state: the higher the score, the greater the likelihood that the patient may require additional monitoring due to potential acute deterioration.

The 1Bio™AI-Acute is readily available to healthcare professionals through Respiree's 1Bio™ platform, which recently received regulatory clearance together with the RS001 wearable device. With this milestone, the 1Bio™AI-Acute toolbox, the 1Bio™platform, and the RS001 wearable are all now approved by HSA.

With the HSA approval for the 1Bio™AI-Acute toolbox, Respiree is now setting its sights on expanding the 1Bio™AI-Acute regulatory approvals across other APAC and ANZ regions, as well as in the United States, in the coming months.